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Strengths and limitations of this study
 ► This study made several proposals to improve the 
information conveyed by Kaplan–Meier plots for sur-
vival data. Unlike many proposals for graphics, the 
study involved a survey of stakeholders’ opinions.
 ► A total of 1174 people participated in the survey 
representing diverse professions, geographical lo-
cations and amounts of experience.
 ► As a web-based survey for which participants se-
lected themselves, it is not possible to know the 
number that might have participated and therefore 
the response proportion for this survey is unknown.
AbStrACt
Objectives To examine reactions to the proposed 
improvements to standard Kaplan–Meier plots, the 
standard way to present time-to-event data, and to 
understand which (if any) facilitated better depiction of (1) 
the state of patients over time, and (2) uncertainty over 
time in the estimates of survival.
Design A survey of stakeholders’ opinions on the 
proposals.
Setting A web-based survey, open to international 
participation, for those with an interest in visualisation of 
time-to-event data.
Participants 1174 people participated in the survey 
over a 6-week period. Participation was global (although 
primarily Europe and North America) and represented 
a wide range of researchers (primarily statisticians and 
clinicians).
Main outcome measures Two outcome measures were 
of principal importance: (1) participants’ opinions of each 
proposal compared with a ‘standard’ Kaplan–Meier plot; 
and (2) participants’ overall ranking of the proposals 
(including the standard).
results Most proposals were more popular than the 
standard Kaplan–Meier plot. The most popular proposals 
in the two categories, respectively, were an extended table 
beneath the plot depicting the numbers at risk, censored 
and having experienced an event at periodic timepoints, 
and CIs around each Kaplan–Meier curve.
Conclusions This study produced a high response 
number, reflecting the importance of graphics for time-to-
event data. Those producing and publishing Kaplan–Meier 
plots—both authors and journals—should, as a starting 
point, consider using the combination of the two favoured 
proposals.
IntrODuCtIOn
Kaplan–Meier (KM) plots are ubiquitous in 
medical research, depicting the estimated 
cumulative proportion of people surviving 
over time.1 2 This is sometimes presented 
overall, but frequently within groups, such as 
randomised arms of a clinical trial. For a clear 
and simple description of how the KM esti-
mate is calculated, see Ref. 3. In producing 
even a simple KM plot, there are many 
choices to be made, leading to wide variation 
in presentation quality.
Figure 1 gives one example of a KM plot 
(based on data from the RT01 trial).4 Box 1 
outlines the basic anatomy of a KM plot and 
highlights some of the choices to be made for 
readers who are unfamiliar.
The utility of a KM plot depends on who 
is using it and their purpose. Potential users 
may be: members of data monitoring commit-
tees considering interim data; systematic 
reviewers extracting data for meta-analysis; 
trial designers looking for information from 
relevant patients for sample size calculations; 
clinicians trying to understand and communi-
cate survival to their patients; and those inter-
ested in the value of an estimand that was not 
reported, such as restricted mean survival 
times. Even when produced with care, key 
information may still be lacking for certain 
readers. It may seem that KM plots do not 
require much ‘learning to read’. However, we 
have many times been asked by collaborators 
how to read them.
We can learn a lot from a KM plot: the esti-
mated survival fraction at various times; the 
difference in survival fractions between two 
groups; quantiles of survival time; sugges-
tions that hazard functions may be non-pro-
portional.5 It is even possible to reconstitute 
(data similar to) the underlying survival data 
based on KM plots, often very accurately.6
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Figure 1 An example of a Kaplan–Meier plot from the RT01 
trial.
box 1 Anatomy of a Kaplan–Meier plot
In figure 1, the vertical axis runs from 0 to 1 and the horizontal from 0 
to 12 years post randomisation (though this was not the longest fol-
low-up available). The Kaplan–Meier estimate for the control arm is 
depicted by a red-dashed line and for the research arm by a solid blue 
line. The ‘curves’ are stepped over time because the estimate changes 
only at times when an event has occurred. These steps become more 
pronounced over time as more participants are censored. Beneath the 
horizontal axis is a table that reports the number of participants still 
‘at-risk’ at specific time points (here 0, 2, 4, 6, 8, 10 and 12 years), 
that is, they are still in follow-up at this time point, not having had an 
event or been censored. In figure 1, after 10 years, there remain 71 and 
99 participants at risk of an event in the control and research arms, 
respectively.
Despite the above strengths, there are many issues 
which may hinder interpretation of KM plots. The two 
key factors, and the focus of this work, are to communi-
cate clearly:
1. The number of participants at risk, censored and hav-
ing experienced an event at specific times, over time.
2. The uncertainty of the KM estimate over time.
These aspects could aid interpretation and increase 
the amount of information conveyed by KM plots. We 
believe a central problem is that a standard KM plot does 
not clearly show that the right-hand portion of the curve 
(at later time points when there are usually considerably 
fewer patients at risk) is estimated with much greater 
uncertainty than the left-hand portion of the curve. As a 
consequence, we are concerned that many consumers of 
KM curves place undue emphasis on differences between 
curves at these later time points when differences are 
much more likely due to chance.
As a snapshot describing recent practice, we reviewed 
the KM plots presented in articles published in the 
BMJ, JAMA (The Journal of the American Medical Asso-
ciation), The Lancet and NEJM (The New England 
Journal of Medicine) during 2013. In total, there were 50 
randomised, superiority trials with a time-to-event primary 
outcome. The two dominant specialities were cardiovas-
cular disease (22 trials, 44%) and cancer (11 trials, 22%). 
Forty-seven plots (94%) included a table of the numbers 
at risk over time, 10 (20%) depicted censoring in some 
way, either within a table beneath the plot or as ticks on 
the lines, and 5 (10%) depicted uncertainty using some 
form of CI.
The objectives of this work are first, to identify alterna-
tives in relation to the above issues, and second, to under-
stand which (if any) alternatives offer improvements to 
standard practice.
MethODS
Resulting directly from the objectives, the two activities 
undertaken were:
1. To propose some improvements in KM plots.
2. To survey stakeholders in order to understand which 
are preferred.
Graph development
The constraint on activity (1) was that any proposals 
should still principally contain a figure showing the KM 
estimate over time and should not be based on a different 
visual description of survival data (such as those in Refs. 
7 and 8).
A number of proposals were conceptualised, created 
and triaged. These were taken forward on the basis of 
being reasonably different to one another and favoured 
by at least one of the authors. This resulted in six proposals 
to take to survey, including four alternative means of 
representing the numbers at risk and two means of repre-
senting uncertainty.
Sources of data and randomisation
With the aim of covering a range of scenarios, we created 
the proposals for three published, phase III randomised 
trials:
1. RT01: a two-arm trial in prostate cancer which showed 
a clear difference in biochemical progression-free 
survival.4
2. ICON7: a two-arm trial in ovarian cancer with crossing 
survival curves.9
3. LY099: a three-arm trial in Hodgkin’s lymphoma with 
limited differences between the arms.10
Participants were invited to take a short survey of 13 
questions relating to these proposals.
To avoid the repetition and burden of answering all 
questions for each of the three trials, participants were 
randomly assigned to see graphs for just one of the 
trials, using simple randomisation in a 1:1:1 ratio (via a 
JavaScript tool invoked when a participant clicked the 
link to take the survey). The purpose of this randomis-
ation was not to compare the randomised groups (as in 
a randomised trial) but to elicit opinions averaged over 
these three scenarios.
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Figure 2 Proposed graphs using the RT01 data. (A) An 
extended table showing the status of participants over time. 
(B) A plot of the number of participants at risk over time by 
arm. (C) A plot of the status of participants over time by arm, 
beneath the Kaplan–Meier plot. (D) Two plots of the status of 
participants over time, one for each arm, behind the Kaplan–
Meier plot. (E) CIs presented around the Kaplan–Meier 
estimate. (F) Fading of the Kaplan–Meier lines as information 
reduces.
Survey overview
The survey asked for participants’ opinions and prefer-
ences regarding the six alternatives as compared with a 
reference that we regard as a reasonably ‘standard’ KM 
plot (similar to figure 1; note that what constitutes stan-
dard is subject to opinion). The proposals are shown in 
figure 2 (for the RT01 trial data, with standard based on 
authors’ consensus). Larger versions of each graph are 
given in the online supplementary file (online supple-
mentary figures 1–18) for all three trials.
In order to understand which of these proposals were 
preferred by stakeholders, we conducted a survey using 
Online Surveys (formerly BOS).11
taking the survey
Participants were shown each proposed graph and asked 
to score it on a five-point ordinal scale, against the refer-
ence graph (without the proposed alteration, similar to 
that in figure 1), with the reference and proposal options 
visible side by side. The options were ‘Less useful’, 
‘Equal/no preference’, ‘A bit more useful’, ‘Somewhat 
more useful’ and ‘Much more useful’. Participants were 
next asked to rank (in order) up to three preferred 
proposals and to not rank any proposal that they disliked. 
This ranking was done separately, once for the proposals 
addressing the numbers at risk and once for those 
addressing uncertainty.
After answering each of the above questions, partici-
pants had an opportunity to provide free-text comments, 
and a further opportunity to provide general comments 
on the survey. This gave a chance to explain their ratings 
of graphs. All of the free-text comments were read and 
categorised by the authors, with participants’ comments 
assigned completely at random to one of BCO, CIJ, MJS, 
TPM or WJC. These comments were categorised in two 
ways. First, many of the comments were categorised as 
being to criticise, praise or suggest improvements to one 
of the proposals (most proposal-specific comments fell 
into one of these categories). Second, we categorised 
further comments (not proposal specific) according to 
the comments made.
baseline information collected
As well as opinions, we collected some participant character-
istics. For descriptive purposes, we collected the country in 
which participants are primarily based, the date on which the 
survey was taken, and the years of experience (1) ‘reading 
and interpreting’, and (2) ‘creating’ KM graphs. To explore 
whether opinions varied according to two specific charac-
teristics, we also asked what participants identified as their 
principal professional background and whether or not 
they currently act as a journal editor. We regard the latter as 
important because journals often specify styles for KM plots 
(either in instructions to authors or during typesetting) and 
so editors may exert disproportionate influence over what 
appears in the literature.
recruiting participants
We recruited participants by publicising the survey through 
many channels: emails to colleagues and collaborators, 
Twitter, email lists including AllStat and the ISCB (Interna-
tional Society for Clinical Biostatistics) list, clinical collab-
orators of the MRC Clinical Trials Unit at UCL, the UK 
Hubs for Trials Methodology Research (note that this list 
is non-exhaustive). As the survey ran, we noted the high 
proportion of participants whose primary role was statisti-
cian, and so targeted clinicians and systematic reviewers more 
purposefully.
Analysis of results
Analysis of the data is descriptive, generally depicting the 
frequency of specific responses in graphs. The data on which 
the analysis is based are provided in the online supplemen-
tary file for readers to explore themselves, minus the date of 
survey, free-text comments and participant country.
note on ‘sampling’
The survey did not have any formal sampling mechanism 
(or well-defined units of the population, or its size) and 
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Figure 3 Descriptive characteristics of participants (n=1274) as a dot chart (% on horizontal axis; frequencies labelled directly). 
K-M, Kaplan–Meier.
is a convenience sample. We targeted those that we view 
as users and/or creators of KM plots and who we could 
reach, for example, registered clinical trials units in the 
UK, journal editors and systematic reviewers.
Data availability
De-identified data containing individual responses to 
the survey will be made openly available on publication. 
De-identification necessarily required removal of some of 
the descriptive variables, including free-text comments 
(some comments made participants identifiable) and 
country (continent is retained).
reSultS
One thousand, two hundred and seventy-four partici-
pants completed the survey between 26 April 2017 and 
7 July 2017.
Figure 3 gives descriptive information about the partic-
ipants: self-described primary role/training, country in 
which they primarily work, whether they act as a journal 
editor, and experience (1) reading/interpreting and (2) 
producing KM plots. Online supplementary figure 19 is 
a plot of experience reading/interpreting vs producing KM 
plots.
The most represented roles were statistician (727; 57%) 
and clinician (341; 27%). Several other groups were well 
represented (see figure 3), but the results will be domi-
nated by the groups identifying themselves as statistician 
or clinician. One hundred and seventy (14%) respon-
dents identified themselves as journal editors. Partici-
pants were based primarily in the UK and USA but 36% 
were based in other countries, representing all populated 
continents (see figure 3).
Participants’ opinions on the proposed alterations 
to KM plots are given in figure 4. The upper row of 
figure 4A contains the proposals for presenting how 
the number at risk changes over time, the lower row of 
figure 4A for those depicting uncertainty. On the upper 
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Figure 4 (A) Opinion of alteration versus ‘standard’ Kaplan–Meier plot. Upper row is for alterations in presenting numbers 
at risk; lower row is for alterations in depicting uncertainty. (B) Participants’ overall preferences for presenting numbers at risk 
(upper part) and depicting uncertainty (lower part).
row, the extended risk table garnered the most positive 
opinions, with 1054 (83%) participants giving a positive 
response. Some (110 participants; 9%) found this extra 
information ‘less useful’. Using a line graph to depict the 
numbers at risk was not popular, with 574 (45%) finding 
this less useful than the usual table depicting numbers at 
risk. The graph of areas to replace the extended risk table 
divided opinion: while 347 (27%) found it less useful than 
a standard plot, 772 (61%) found it ‘a bit’, ‘somewhat’ or 
‘much more’ useful. The same chart with the areas super-
imposed behind the KM estimate was much less popular, 
with 720 (57%) finding it less useful than the usual plot 
(at this first exposure). The lower row shows ambivalence 
about the idea of faded lines: 545 (43%) found this less 
useful than a standard presentation, 195 (15%) had no 
preference and 534 (42%) found it more useful.
These results were broadly similar across the three 
trials, both for statisticians and clinicians, and for editors 
and non-editors of journals. Figures similar to the upper 
panel of figure 4, broken down by these groups, can be 
found in the online supplementary file.
Figure 4B gives participants’ overall rankings for the 
proposals, separately for those addressing numbers at 
risk and uncertainty. Green bars depict the number of 
participants who ranked this graph as their first choice; 
orange as second, red as third and grey not ranked (for 
proposals depicting uncertainty, although there were 
only three options, participants did not have to answer 
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Figure 5 The two most popular elements combined: CIs 
and extended at-risk table.
for all choices if, eg, they found only one option to be 
acceptable). These results give the same message as those 
presented in figure 4A. For presenting numbers at risk, 
an extended risk table is the clear favourite; for depicting 
uncertainty, the use of CIs was the first choice for over 
half the participants.
An idea of the nature of free-text responses is provided 
in online supplementary figure 20, which summarises 
whether graph-specific comments were criticism, praise or 
suggestions (left) and gives the broad types of comment 
(right).
DISCuSSIOn
We have proposed several alterations to standard KM 
plots, specifically for the context of showing within-arm 
survival in randomised trials. The proposals were around 
two key aspects depicting: (1) the numbers at risk over 
time and (2) uncertainty.
We then surveyed users of KM plots for their views on 
our proposals. Several garnered more positive opinions 
than the reference plot, and two came out as the overall 
favourites, although opinions were far from unanimous.
We do not make explicit recommendations here about 
which alterations should be used but encourage producers 
of KM plots and those who influence them (journal editors 
and regulators) to consider their practice in light of these 
results. In particular, the plots including an extended 
table of numbers and CIs seemed to be favoured by most 
participants. These can be used in combination without 
any clash, and we include an example with both aspects in 
figure 5, again using the RT01 data.
There is clear recognition that graphical representa-
tions of time-to-event data could be improved. Many free-
text responses noted context. KM plots are used by: trial 
designers looking for previous information on a related 
group of patients; data monitoring committees viewing 
interim data; meta-analysts to extract data and clinicians 
looking to understand and communicate risks to their 
patients. There is no one size that fits all settings and 
producers of KM plots need to make judicious choices 
according to their context.
The two proposals involving area graphs to depict the 
number at risk require some thought to understand 
and are not instantly readable; a graph that requires 
little ‘learning to read’ is perhaps desirable. These two 
proposals were broadly unpopular in the survey: many 
commented that this depiction was confusing, but a 
minority who liked them said it took time to reach that 
conclusion. Prior to the survey, the authors had expected 
the KM curve superimposed on the area depicting 
numbers at risk to be more popular than they were. The 
results of the survey show the desirability of a graph that 
requires little ‘learning to read’ and also the importance 
of a large stakeholder survey to elicit representative 
preferences.
Depicting the numbers at risk using line charts below 
the KM plot was also reasonably unpopular. Free-text 
comments suggested three main reasons: (1) partici-
pants wanted specific numbers in preference to a general 
pattern; (2) the line looks similar to the line of the KM 
estimate, leading to potential confusion; and (3) as we 
created and presented this option, the plot region for 
the numbers in follow-up used 1/3 the area of the plot 
region for the KM estimate, which for some participants 
was inadequate—a poor choice on our part. This propor-
tion would need to be reconsidered by anyone looking to 
use the approach.
For depicting uncertainty, fading the KM estimates was 
unpopular. There were two principal reasons for this. 
First, when printed, the fading could be confused for a 
printing error, rather than an intended effect. Second, 
it is not clear how to define the level of decreasing inten-
sity that accurately reflects the readers’ perception of 
increasing uncertainty. A minor comment from some 
clinicians was the desire to be able to accurately read the 
estimate at a very late time point (note that the premise 
for use of fading was in part to prevent this where uncer-
tainty is extremely high).
Further thought is required on visualising survival 
data, and new proposals would ideally be accompanied 
by studies on stakeholders’ opinions. We constrained this 
project to KM plots with two or more groups. However, in 
a randomised trial, we are interested in comparing arms 
and so want to visualise some estimate of the difference. 
Such visualisations may be a fruitful future direction.
Interestingly, Paul Meier himself is said to have spoken 
with bemusement about people plotting KM estimates 
over time and was not convinced he actually liked it (the 
authors thank Chris Barker, a former student of Meier, 
for this personal communication).
As noted in the Methods section, the trial datasets we 
used do not represent any true distribution of scenarios 
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occurring in clinical trials. Rather, they represent a small 
variety of situations which can occur in randomised trials; 
for any change to KM plots to be worthwhile, the impact 
of features such as non-inferiority, non-proportional 
hazards, more than two arms and different allocation 
ratios should be assessed. Having said this, if a plot works 
well for two-arm trials but not three-arm trials, it may of 
course be used in that context.
We hope that this work will provoke those creating 
KM plots to think carefully about how they can best 
convey the information, and that journal editors will 
consider their policies for rendering KM plots. We will 
continue to consider alternatives and evaluate these in 
the future.
Patient and public involvement
There was no formal patient and public involvement in 
the development of the KM proposals but patients were 
an important group of participants who were actively 
targeted by our survey. Alongside the researchers, 19 
patients participated. Our objective was to improve 
researchers’ understanding of KM plots. The survey itself 
was an attempt to involve such researchers by asking for 
their views on our proposals.
Dissemination declaration
We will email results to all survey participants who stated 
that they wished to be updated. This will be done to coin-
cide with publication of the manuscript.
twitter Tim P Morris @tmorris_mrc, Christopher I Jarvis @TheJarvisC1, Patrick P 
J Phillips @PPJPhillips, Babak Choodari-Oskooei @BabakOskooei and Matthew R 
Sydes @mattsydes
Acknowledgements The authors are grateful to the 1274 participants who 
provided their opinions, particularly those who pointed us to articles containing 
their own thoughts on Kaplan–Meier; to the ICON7, LY09 and RE01 trial teams and 
participants for the use of these data.
Contributors The initial idea for this project came from TPM and MRS. All authors 
were involved in the initial planning, design and running of the study. TPM and 
CIJ checked and cleaned the data and TPM analysed the results. All authors 
commented critically on and approved the manuscript.
Funding This work was supported by the Medical Research Council (grant 
numbers MC_UU_12023/21, MC_UU_12023/29 and MC_UU_12023/24)—TPM, 
WC, PP, BC-O, MRS.
Competing interests None declared.
Patient consent for publication Not required.
ethics approval No ethical approval was required (or obtained), assessed using 
the online HRA decision tool. This was a survey of opinions on a non-sensitive 
subject, collecting no biological samples or data that might be identifiable (unless 
participants identified themselves in a free-text comment or chose to provide 
contact details to hear about the results of the survey).
Provenance and peer review Not commissioned; externally peer reviewed.
Data availability statement All shareable data relevant to the study are available 
on the UCL Research Data Repository.
Open access This is an open access article distributed in accordance with the 
Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits 
others to copy, redistribute, remix, transform and build upon this work for any 
purpose, provided the original work is properly cited, a link to the licence is given, 
and indication of whether changes were made. See: https:// creativecommons. org/ 
licenses/ by/ 4. 0/.
OrCID iDs
Tim P Morris http:// orcid. org/ 0000- 0001- 5850- 3610
Christopher I Jarvis http:// orcid. org/ 0000- 0002- 0812- 2446
William Cragg https:// orcid. org/ 0000- 0002- 1274- 8521
Patrick P J Phillips https:// orcid. org/ 0000- 0002- 6336- 7024
Babak Choodari-Oskooei https:// orcid. org/ 0000- 0001- 7679- 5899
Matthew R Sydes http:// orcid. org/ 0000- 0002- 9323- 1371
reFerenCeS
 1. Kaplan EL, Meier P. Nonparametric estimation from incomplete 
observations. J Am Stat Assoc 1958;53:457–81.
 2. Pocock SJ, Travison TG, Wruck LM. Figures in clinical trial reports: 
current practice & scope for improvement. Trials 2007;8:36.
 3. Bland JM, Altman DG. Survival probabilities (the Kaplan-Meier 
method). BMJ 1998;317:1572–80.
 4. Dearnaley DP, Jovic G, Syndikus I, et al. Escalated-dose versus 
control-dose conformal radiotherapy for prostate cancer: long-term 
results from the MRC RT01 randomised controlled trial. Lancet Oncol 
2014;15:464–73.
 5. Ford I, Norrie J. The role of covariates in estimating treatment effects 
and risk in long-term clinical trials. Stat Med 2002;21:2899–908.
 6. Guyot P, Ades AE, Ouwens MJNM, et al. Enhanced secondary 
analysis of survival data: reconstructing the data from published 
Kaplan-Meier survival curves. BMC Med Res Methodol 2012;12:9.
 7. Newell J, Kay JW, Aitchison TC] . Survival ratio plots with 
permutation envelopes in survival data problems. Comput Biol Med 
2006;36:526–41.
 8. Royston P, Parmar MKB, Altman DG. Visualizing length of survival in 
time-to-event studies: a complement to Kaplan-Meier plots. J Natl 
Cancer Inst 2008;100:92–7.
 9. Oza AM, Cook AD, Pfisterer J, et al. Standard chemotherapy with 
or without bevacizumab for women with newly diagnosed ovarian 
cancer (ICON7): overall survival results of a phase 3 randomised trial. 
Lancet Oncol 2015;16:928–36.
 10. Johnson PWM, Sydes MR, Hancock BW, et al. Consolidation 
radiotherapy in patients with advanced Hodgkin's lymphoma: 
survival data from the UKLG LY09 randomized controlled trial 
(ISRCTN97144519). J Clin Oncol 2010;28:3352–9.
 11. Online surveys (formerly Bos), 2019
Tropical M
edicine. Protected by copyright.
 o
n
 O
ctober 23, 2019 at London School of Hygiene and
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2019-030215 on 30 September 2019. Downloaded from 
